

Nectar Lifesciences Ltd.

Ref No. NLL/CS/2013-421



Dated: 13.11.2013

1. National Stock Exchange of India Limited
'G' Block, Exchange Plaza, Bandra Kurla Complex,
Bandra (East), MUMBAI – 400 051.
2. Bombay Stock Exchange Limited
Phiroze Jeejeebhoy Towers, Dalal Street,
MUMBAI – 400 001.

Sub: Compliance under Clause 41 the Listing Agreement.

Sirs,


Pursuant to Clause 41 of the Listing Agreement, please find enclosed herewith a copy of the Unaudited Financial Results for the period ended on September 30, 2013, as approved by the Board of Directors in their meeting held on even date i.e. November 13, 2013.

Kindly take the same on record and oblige.

Thanking you,

Yours truly,

For Nectar Lifesciences Limited


Sunder Lal
Company Secretary

Encl. as above

CC:- Societe de la Bourse de Luxembourg S.A.
BP 165, L-2011 Luxembourg,
Telephone : (00352) 47 79 38-1
Fax: (00352) 47 32 98






NECTAR LIFESCIENCES LIMITED

Regd. Office: VIII, Saidpura, Tehsil Derabassi, Distt. Mohali, (Punjab)

Statement of Unaudited Financial Results for the Quarter and Six Months ended 30.09.2013 (Rs in Lacs)

S. No	PARTICULARS	Quarter ended 30-09-2013				Half Year ended 30-09-2013				Year ended 31-03-2013	
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
1.	Income from Operations										
	(a) Gross Sales	45749.04	36150.94	50582.52	81899.98	90995.73	167324.71				
	Less : Excise Duty	1597.38	1669.68	1108.49	3267.06	2166.70	4843.28				
	Net Sales	44151.66	34481.26	49474.03	78632.92	88829.03	162481.43				
	(b) Other Operating Income	6.89	6.53	52.77	13.42	114.62	143.67				
	Total Income from Operations (net)	44158.55	34487.79	49526.80	78646.34	88943.65	162625.10				
2.	Expenses										
	(a) Cost of Materials consumed	31105.68	24567.84	36940.47	55673.52	61207.09	114852.24				
	(b) Purchase of Stock in Trade	520.22	2736.95	990.62	3257.17	4490.48	5999.80				
	(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	(810.18)	(2948.51)	(331.98)	(3758.69)	1149.03	(6440.21)				
	(d) Employee benefits expense	1256.49	1398.7	1149.93	2655.19	2224.99	4861.11				
	(e) Depreciation and amortisation expense	2098.93	2139.51	1919.59	4238.44	3712.19	7595.61				
	(f) Other expenses	4443.18	2924.94	3678.50	7368.12	6734.80	14544.15				
	Total Expenses	38614.32	30819.43	44347.13	69433.75	79518.58	141212.70				
3.	Profit from Operations before Other Income, finance costs and exceptional items (1-2)	5544.23	3668.36	5179.67	9212.59	9425.07	21412.40				
4.	Other Income	429.04	398.86	412.71	827.90	824.70	1604.03				
5.	Profit before finance costs and exceptional items (3+4)	5973.27	4067.22	5592.38	10040.49	10249.77	23016.43				
6.	Finance costs	3941.79	2576.78	2767.91	6518.57	5260.68	11548.93				
7.	Profit after finance costs but before exceptional items (5-6)	2031.48	1490.44	2824.47	3521.92	4989.09	11467.50				
8.	Exceptional items	0.00	0.00	0.00	0.00	0.00	0.00				
9.	Profit from ordinary activities before tax (7+8)	2031.48	1490.44	2824.47	3521.92	4989.09	11467.50				
10.	Tax Expense	513.83	382.82	569.53	896.65	1131.38	2900.95				
11.	Net Profit from ordinary activities after tax (9-10)	1517.65	1107.62	2254.94	2625.27	3857.71	8566.55				
12.	Extraordinary item (net of tax expense)	0.00	0.00	0.00	0.00	0.00	0.00				
13.	Net Profit for the period (11-12)	1517.65	1107.62	2254.94	2625.27	3857.71	8566.55				
14.	Paid up Equity Share Capital (Face Value per share : Re.1/-)	2,242.61	2,242.61	2,242.61	2,242.61	2,242.61	2,242.61				
15.	Reserves excluding Revaluation Reserves	-	-	-	-	-	84,517.96				
16.i	Earnings per Share (EPS) (before extraordinary items)										
	a) Basic	0.68	0.49	1.01	1.17	1.72	3.82				
	b) Diluted	0.68	0.49	1.01	1.17	1.72	3.82				
16.ii	Earnings per Share (EPS) (after extraordinary items)										
	a) Basic	0.68	0.49	1.01	1.17	1.72	3.82				
	b) Diluted	0.68	0.49	1.01	1.17	1.72	3.82				



Part II Select Information for the Quarter and six month ended 30.09.2013									
A	Particulars of shareholding								
1.	Public Shareholding								
	- Number of Shares	124,792,970	124,792,970	124,792,970	124,792,970	124,792,970	124,792,970	124,792,970	124,792,970
	- Percentage of Shareholding	55.65	55.65	55.65	55.65	55.65	55.65	55.65	55.65
2.	Promoters and Promoter Group Shareholding								
	a) Pledged/Encumbered								
	- Number of Shares	-	-	-	-	-	-	-	-
	- Percentage of Shares (as a % of the total shareholding of promoter and promoter group)	-	-	-	-	-	-	-	-
	- Percentage of Shares (as a % of the total share capital of the company)	-	-	-	-	-	-	-	-
	b) Non-encumbered								
	- Number of Shares	99,468,000	99,468,000	99,468,000	99,468,000	99,468,000	99,468,000	99,468,000	99,468,000
	- Percentage of Shares (as a % of the total shareholding of promoter and promoter group)	100.00	100.00	100.00	100.00	100.00	100.00	100.00	100.00
	- Percentage of Shares (as a % of the total share capital of the company)	44.35	44.35	44.35	44.35	44.35	44.35	44.35	44.35
B	3 Months ended 30.09.2013								
	Investor Complaints								
	Pending at the beginning of Quarter								
	Received During the Quarter			18					
	Disposed Off During the Quarter			18					
	Pending at the end of Quarter								
Statement of Assets and Liabilities									
PARTICULARS									
(Rs in Lacs)									
							As at	As at	
							30-09-2013	31-03-2013	
							Unaudited	Audited	
SHAREHOLDERS' FUND									
(i) Capital							2,242.61	2,242.61	2,242.61
(ii) Reserves and Surplus							87,243.22	84,517.96	84,517.96
NON CURRENT LIABILITIES									
(i) Long Term Liabilities							22,826.92	26,096.08	26,096.08
(ii) Deferred Tax Liability							10,094.02	9,575.63	9,575.63
(iii) Other Long Term Liabilities							85.49	102.99	102.99
CURRENT LIABILITIES							378.88	378.88	378.88
(i) Short Term Borrowings									
(ii) Trade Payables							54,013.97	50,911.14	50,911.14
(iii) Other Current Liabilities							41,995.39	38,251.85	38,251.85
(iv) Short Term Provisions							13,583.67	13,127.61	13,127.61
							2,945.94	2,199.56	2,199.56
							235,410.11	227,404.31	227,404.31



- NON CURRENT ASSETS**
- (i) Fixed Assets (Incl CWIP)
- (ii) Non Current Investments
- (iii) Long Term Loans & Advances
- (iv) Other Non Current Assets
- CURRENT ASSETS**
- (i) Current Investments
- (ii) Inventories
- (iii) Trade Receivables
- (iv) Cash & Bank Balances
- (v) Short Term Loans & Advances
- (vi) Other Current Assets

105,730.07	105,240.84
5.01	5.01
7,408.65	7,048.61
1.31	1.50
31.92	31.92
75,583.36	67,600.04
37,891.91	34,938.64
333.10	624.04
6,111.03	8,684.33
2,313.75	3,229.38
235,410.11	227,404.31

Notes:

- The above financial results were reviewed by Audit Committee on 12.11.13 and approved by the Board in its meeting held on even date i.e. 13.11.13 and further limited reviewed by the Statutory Auditors of the Company.
- The company is exclusively in the pharmaceutical business segment.
- The Shareholders in their Annual General Meeting held on 30.09.2013 have declared the final dividend of Re. 0.10/- per equity share (10% on the face value of Re. 1/- per equity share) for the financial year 2012-13. The Company has despatched Dividend Warrants to the shareholders at their registered addresses, and wherever applicable, the Dividend has been credited to the shareholders' accounts directly through National Electronic Credit Settlement (NECS/ECS/NEFT/ Direct Credit) facility of RBI.
- Previous year figures have been regrouped and reclassified wherever necessary to make them comparable with current period.
- As per Accounting Standard 11, accounting of the effect of changes in foreign exchange rates will be ascertained at the end of the year and hence the same is not considered in these quarterly results.
- The above financial results are on stand alone basis.

Dated: 13.11.2013

Place: Chandigarh

Certified to be true copy

For Nectar Lifesciences Limited

Sunder Lal
Company Secretary

By Order of the Board of Directors
of Nectar Lifesciences Limited

Sd/-

(Dinesh Dua)
Chief Executive Officer & Director